RE:RE:RE:RE:RE:RE:Best Option? This is what happens when you turn your back on the retail investors, as I said it is in broker's interest to have the SP appreciate from the bought deal's price so they can sell it to their clients with a premium but they are against 85% of current retail holders of the company who are bailing out today tired of waiting even so within few months the company is initiating the oncology and yes I have no doubts the NASH phase 3.
Even the early financing would seems like the the company is less confident about the outcome I think the reason for financing is purely a defensive strategy for a company with little risk tolerance.
All the clinical trials are not slam dunk process but this financing has nothing to do with the change of the company's view of the success/failures of programs imo.
Having said that it is a shame that they didn't have enough courage to wait and time the deal to a later date as a result uneducated large amount of the investors get the picture of a less confident company and bailed out.
It should really be the opposite meaning company would delay the offering avoiding all the angst among the retail investors. In my opinion nothing has changed as per promising prospects of the company and as I always been hoping the company needs to not only execute but follow that with proper marketing, this is even more crucial after the financing with new shareholders will be joining the company, they need to convert them to investors.